Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma

BACKGROUND: Gliosarcoma is a rare variant of glioblastoma (GBM) that exhibits frequent mutations in TP53 and can develop in a secondary fashion after chemoradiation of a primary GBM. Whether temozolomide (TMZ)-induced mutagenesis of the TP53 DNA-binding domain (DBD) can drive the pathogenesis of gli...

Descripción completa

Detalles Bibliográficos
Autores principales: Pain, Margaret, Wang, Huaien, Lee, Eunjee, Strahl, Maya, Hamou, Wissam, Sebra, Robert, Zhu, Jun, Yong, Raymund L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788663/
https://www.ncbi.nlm.nih.gov/pubmed/29416795
http://dx.doi.org/10.18632/oncotarget.23517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788663/
https://www.ncbi.nlm.nih.gov/pubmed/29416795
http://dx.doi.org/10.18632/oncotarget.23517

Ejemplares similares